Latest developments in mHSPC
Prof Kurt Miller and Prof Laura-Maria Krabbe
Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )
25 Feb 2022
Evaluating a polygenic hazard score to predict risk of developing metastatic or ...
Dr Meghana Pagadala - University of California San Diego, San Diego, USA
Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer ( Dr Meghana Pagadala - University of California San Diego, San Diego, USA )
25 Feb 2022
ASCO GU 2022: The latest in CRPC, including PARP combo data
Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Mers...
ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )
25 Feb 2022
Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma o...
Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Nether...
Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis ( Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Netherlands )
24 Feb 2022
Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in a...
Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spai...
Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
21 Feb 2022
KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant th...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
21 Feb 2022
ASCO GU 2022: What to watch out for in renal
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2022: What to watch out for in renal ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
21 Feb 2022
Maintenance PARP inhibition following chemotherapy for metastatic urothelial car...
Dr Simon Crabb - University of Southampton, Southampton, UK
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma ( Dr Simon Crabb - University of Southampton, Southampton, UK )
21 Feb 2022
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients...
Prof Alfredo Berruti - University Of Brescia, Brescia, Italy
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. ( Prof Alfredo Berruti - University Of Brescia, Brescia, Italy )
21 Feb 2022
Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladde...
Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )
21 Feb 2022
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Feb 2022
OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology
Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBri...
OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology ( Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBride, Dr Ravindran Kanesvaran & Dr Nicolo Battisti )
19 Jan 2022